UY26088A1 - Inhibidores de proteasas - Google Patents

Inhibidores de proteasas

Info

Publication number
UY26088A1
UY26088A1 UY26088A UY26088A UY26088A1 UY 26088 A1 UY26088 A1 UY 26088A1 UY 26088 A UY26088 A UY 26088A UY 26088 A UY26088 A UY 26088A UY 26088 A1 UY26088 A1 UY 26088A1
Authority
UY
Uruguay
Prior art keywords
disease
cartilage
matrix
excessive
proteases
Prior art date
Application number
UY26088A
Other languages
English (en)
Inventor
Dennis Shinji Yamashita
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY26088A1 publication Critical patent/UY26088A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/12—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona inhibidores de proteasas de 4-amino-4, 5 -dihidro-benzo [b] [1, 4] dioxocin- 3 -ona, y sus sales, hidratos y solvatos farmacéuticamente aceptables que inhiben las proteasas, con inclusión de la catepsina K, composiciones farmacéuticas de tales compuestos, y métodos para tratar enfermedades de pérdida ósea excesiva o degradación excesiva de cartílago o matriz, que incluyen osteoporosis; enfermedad gingival con inclusión de gingivitis y periodontitis, artritis, más específicamente osteoartritis y artritis reumatoide; enfermedad de Paget; hipercalcemia de carácter maligno; y enfermedad metabólica ósea, que comprenden inhibir dicha pérdida ósea o degradación excesiva de cartílago o matriz por administración a un paciente que se encuentra en necesidad de ello de un compuesto de la presente invención.
UY26088A 1999-03-31 2000-03-29 Inhibidores de proteasas UY26088A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12725099P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
UY26088A1 true UY26088A1 (es) 2000-10-31

Family

ID=22429122

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26088A UY26088A1 (es) 1999-03-31 2000-03-29 Inhibidores de proteasas

Country Status (8)

Country Link
EP (1) EP1173429A4 (es)
JP (1) JP2002540199A (es)
AU (1) AU4066900A (es)
CO (1) CO5180536A1 (es)
HK (1) HK1044758A1 (es)
PE (1) PE20001607A1 (es)
UY (1) UY26088A1 (es)
WO (1) WO2000058296A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
JP2003513924A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
SK13632002A3 (sk) 2000-03-21 2003-02-04 Smithkline Beecham Corporation C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
WO2003062192A1 (en) 2002-01-17 2003-07-31 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
JP2004196696A (ja) * 2002-12-18 2004-07-15 Kyowa Hakko Kogyo Co Ltd 関節炎の予防剤または治療剤
CN113651795B (zh) * 2021-09-14 2022-09-02 江西开源香料有限公司 一种西瓜酮的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use

Also Published As

Publication number Publication date
WO2000058296A1 (en) 2000-10-05
EP1173429A4 (en) 2002-06-19
AU4066900A (en) 2000-10-16
EP1173429A1 (en) 2002-01-23
JP2002540199A (ja) 2002-11-26
HK1044758A1 (zh) 2002-11-01
CO5180536A1 (es) 2002-07-30
PE20001607A1 (es) 2001-03-07

Similar Documents

Publication Publication Date Title
NO20013124L (no) Protease inhibitorer
UY26625A1 (es) Inhibidores de proteasas
AP9801222A0 (en) Proatease inhibitors.
TR199902703T2 (xx) Proteaz inhibit�rleri.
WO1999059526A3 (en) Protease inhibitors
AP2002002671A0 (en) Protease inhibitors.
UY26088A1 (es) Inhibidores de proteasas
UY26026A1 (es) Inhibidores de proteasas
UY27032A1 (es) Inhibidores de proteasas
WO2002092563A3 (en) Protease inhibitors
ECSP003403A (es) Inhibidores de proteasas xi
ECSP993293A (es) Inhibidores de proteasas viii
ECSP992959A (es) Inhibidores de proteasa de bis- aminometil carbonilo
AR021971A1 (es) Inhibidores de proteasas
ECSP982481A (es) Inhibidores de proteasas
ECSP982486A (es) Inhibidores de proteasas ii
UY26771A1 (es) Inhibidores de proteasas
ECSP003353A (es) Inhibidores de proteasas ix
ECSP982493A (es) Inhibidores de proteasas iii
AR004703A1 (es) Hidrazidil, bis-hidrazil y bis-aminometil-carbonil, inhibidores de proteasas, una composicin farmaceutica, metodo para inhibir proteasas, y uso en la preparacion de medicamentos.
UY24550A1 (es) Inhibidores de proteasa
NZ324101A (en) Protease inhibitors, pharmaceutical compositions and use thereof

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20091022